BAY 43-9006 inhibition of oncogenic RET mutants. - Wikidata - wikimedia - TriplyDB

BAY 43-9006 inhibition of oncogenic RET mutants.

BAY 43-9006 inhibition of oncogenic RET mutants.

http://www.wikidata.org/entity/Q34565246

about

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives The treatment landscape in thyroid cancer: a focus on cabozantinib Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.Medullary thyroid cancer: monitoring and therapy.A novel orthotopic mouse model of human anaplastic thyroid carcinoma New knowledge of the mechanisms of sorafenib resistance in liver cancer Thyroid cancer: current molecular perspectives.A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)Update on thyroid cancer treatment.An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.Novel therapeutic strategies for targeting liver cancer stem cells.Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies Thyroid cancer: emerging role for targeted therapies.Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial New therapies for dedifferentiated papillary thyroid cancer Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Standard and emerging therapies for metastatic differentiated thyroid cancer.Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status Keratoacanthomas associated with sorafenib therapy.Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma

P2860

Q24619987-9BD0FF61-B6B4-4B0E-9662-E75E16AB2643 Q26751274-C6577660-1575-4A83-AB4A-077203086665 Q26796404-E57E78B3-F3A8-4DE0-AFA5-3F777D18B1B6 Q26826817-58AC210C-A461-4B35-B7EB-5028ABB8C4E9 Q27023383-AF14477E-2062-47C6-8FB1-D92B9C89EF9D Q27026753-10F1ECE0-0967-4563-984C-D00E69BBFB33 Q27320669-C79D37BD-8D46-4786-9E77-3940F494F501 Q27652488-E239FD4C-E556-40A3-BA24-6364A0A85B87 Q27851560-860D2034-E552-4F7B-B760-4B773976011A Q28538126-AE7023F2-F99D-4E40-9059-8B1B460F07CE Q33384665-690C65AE-E919-464D-BBBE-514C6BB4AB0D Q33514138-DDF29185-914B-4E21-B265-46D926860542 Q33565239-CD00BA99-D890-4BD7-B67D-09A61CFF01BD Q33591999-3DF6A9F1-5445-4687-8F3F-B2395247FB77 Q33707844-058AADED-CEAF-4C0A-803F-E1757C3D75B3 Q33759933-F376B0F1-819B-4DAD-8473-B5F2552EB841 Q33760910-09476948-1C12-4333-A8F0-8E7409DF23D9 Q33785790-0FE31337-90E6-4BC0-91F9-8268F98FF499 Q33788030-3F56F190-05C2-4667-ACE1-141D77CB5830 Q33889920-7A07BA65-8880-4421-9741-EE9A87B5F8EA Q34310219-302F8086-5674-4F26-AEE3-385A73B168E9 Q34611731-386BB548-63CB-4AD3-99ED-61D8C7AD8596 Q34758477-A1A7395B-B8C4-41FC-A486-71078B87FAB0 Q34786090-C7E48500-112E-45AA-A416-ACFEA09C25AA Q34940971-F747B95C-9D3E-470F-95A6-A0B979BFCC81 Q34948215-A8063311-3F38-45B5-BCEF-08B1FAC1FC30 Q35038893-305183CC-ECB4-472D-BDF4-EBECC82F6FFF Q35076227-F0A1E75A-09CD-478E-A0A3-2CD2489484D5 Q35109163-1553B23B-84BC-465D-A82F-6EA1D1C1ECA9 Q35195766-9703BC66-22AE-4A0E-A4AB-AE71B15C81B0 Q35381593-461EA8AF-09E2-419F-9F98-6B7EE21DF4F7 Q35570953-9B72BEAE-D4D7-4EAD-8E38-13E384775737 Q35583906-C662F8E9-44E7-4EA6-B125-67DFE16AECCA Q35603183-BE063BE4-AAE0-43E9-B3F4-22D6B8A444A6 Q35608349-CB1F85CE-8AAB-4B63-838E-13AD61E6756E Q35691234-AB9D095E-EC71-4522-B61E-34ABBF207E1F Q35914464-4623C813-4C45-46B0-83B0-56A22067B5A5 Q35950143-6FFFB95B-95EA-460A-BFE8-F33B46A25ACD Q36060211-F0BB1441-D019-4E70-8697-9D72DDCEDA17 Q36066995-3B567FB5-F879-400C-8534-33EADF2071DE

P2860

BAY 43-9006 inhibition of oncogenic RET mutants.

http://www.wikidata.org/entity/Q34565246

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

BAY 43-9006 inhibition of oncogenic RET mutants.

@ast

BAY 43-9006 inhibition of oncogenic RET mutants.

@en

BAY 43-9006 inhibition of oncogenic RET mutants.

@nl

type

label

BAY 43-9006 inhibition of oncogenic RET mutants.

@ast

BAY 43-9006 inhibition of oncogenic RET mutants.

@en

BAY 43-9006 inhibition of oncogenic RET mutants.

@nl

prefLabel

BAY 43-9006 inhibition of oncogenic RET mutants.

@ast

BAY 43-9006 inhibition of oncogenic RET mutants.

@en

BAY 43-9006 inhibition of oncogenic RET mutants.

@nl

P1433

Q34565246-47317390-340A-44FC-B01E-0813DCF5AE78

P1476

Q34565246-5463E3F9-E25C-4921-8B23-01EC7A5C67DE

P2093

Q34565246-411339D3-8A9E-44EC-A108-C0061FC932A2

Q34565246-6636A639-AD27-4E1F-A6E0-B668FA7AA5D7

Q34565246-A7499D0C-C8C7-4205-B434-B5F044FDC675

Q34565246-C6A1B4F8-25AB-49CC-B6DE-768BBCDDC72C

Q34565246-E424C6BC-5F40-4DE5-A72B-EC63FD39859C

Q34565246-ED3983C1-9A0D-4712-B218-08E56C2A11D2

Q34565246-F87319A0-FD12-4D0B-BC74-82BFC7CD28FF

P2860

Q34565246-103E819D-11C9-4421-9861-DBEBC8E9374D

Q34565246-3786F689-F97A-4587-93FD-0473042F5B45

Q34565246-3AFBAF49-3553-482E-88B1-6F4C0426EC3A

Q34565246-44EF7F0F-7DA1-4B1C-B454-A05E6E7D52FB

Q34565246-4A38E28E-8C35-459F-8D7A-D176E190FCAE

Q34565246-4AAEC57F-A628-4398-866B-7B073EAE853A

Q34565246-53409F65-A405-4ACA-BB9D-4469CFC2F37D

Q34565246-70CBBBE7-54A3-448A-8BFA-C2E076CCC458

Q34565246-77ACCCE4-6282-4906-A4E1-C342D016236A

Q34565246-7A4F5D3F-BF48-49D3-B22B-C5B99D13A150

P304

Q34565246-F6154C2A-A8EB-43E8-84A1-53D776F7A0A8

P31

Q34565246-CD529EBD-6EC4-4275-89BC-640635781040

P356

Q34565246-C663C37A-380F-40C1-B246-D28337306D13

P407

Q34565246-19BEFFE9-443F-4737-B49D-66E6D7CE9F01

P433

Q34565246-7962DD30-05A1-44C8-8AD8-02C9A6FDFA3B

P478

Q34565246-57B1466A-A970-4EC5-9A33-C1ACEF3511C6

P577

Q34565246-434BD35B-3FD4-4856-8A3E-D0513105F3E8

P5875

Q34565246-F5A94EDC-4C2E-4EAA-AC45-3DC228A0C011

P698

Q34565246-5412AFB8-1F74-4D25-9E88-D1144870F681

P356

P1433

Journal of the National Cancer Institute

P1476

BAY 43-9006 inhibition of oncogenic RET mutants.

@en

P2093

Francesca Carlomagno

http://www.w3.org/2001/XMLSchema#string

Giancarlo Troncone

http://www.w3.org/2001/XMLSchema#string

Giuliana Salvatore

http://www.w3.org/2001/XMLSchema#string

Massimo Santoro

http://www.w3.org/2001/XMLSchema#string

Scott M Wilhelm

http://www.w3.org/2001/XMLSchema#string

Suresh Anaganti

http://www.w3.org/2001/XMLSchema#string

Teresa Guida

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line

Minireview: RET: normal and abnormal functions

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Early malignant progression of hereditary medullary thyroid cancer.

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

P304

326-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJJ069

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7269638

http://www.w3.org/2001/XMLSchema#string

P698

16507829

http://www.w3.org/2001/XMLSchema#string